Clinical Trials

Complete EU pivotal trial data highlights transformative potential of aXess in hemodialysis treatment Primary endpoint met with standout sustained patency…

Preliminary clinical data from Xabg, Xeltis’ coronary artery bypass conduit (CABG), demonstrating positive safety and patency In an earlier, separate…

Enrolment completed - 120 patients with end-stage renal disease in 22 centers in Europe Primary endpoint readouts anticipated in Q2…

Designation recognizes aXess has the potential of providing a more effective vascular access option for dialysis patients, bringing significant advantages…

aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, permanent,…